Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib
Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment li...
Main Authors: | Diana Valentina Tudor, Ioana Bâldea, Diana Elena Olteanu, Eva Fischer-Fodor, Virag Piroska, Mihai Lupu, Tudor Călinici, Roxana Maria Decea, Gabriela Adriana Filip |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/9/4387 |
Similar Items
-
COX-2 as a potential biomarker and therapeutic target in melanoma
by: Diana Valentina Tudor, et al.
Published: (2020-02-01) -
Celecoxib in breast cancer prevention and therapy
by: Li J, et al.
Published: (2018-10-01) -
Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis
by: Ling Sun
Published: (2021-01-01) -
Celecoxib Enhances Radiosensitivity via Induction of G2-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma
by: Shui-xing Zhang, et al.
Published: (2014-05-01) -
Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma
by: Garcia-Recio M, et al.
Published: (2018-10-01)